[미국특허]
Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-048/00
A61K-009/66
C07H-021/04
C12N-015/00
출원번호
US-0163767
(2011-06-20)
등록번호
US-8415318
(2013-04-09)
발명자
/ 주소
Harats, Dror
Greenberger, Shoshana
Breitbart, Eyal
출원인 / 주소
Vascular Biogenics Ltd.
대리인 / 주소
Sterne, Kessler, Goldstein & Fox P.L.L.C.
인용정보
피인용 횟수 :
8인용 특허 :
126
초록▼
A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecul
A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided. The nucleic acid construct includes: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule; and (b) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell, whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule. Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth.
대표청구항▼
1. A method of inducing apoptosis of an endothelial cell in a tumor of a subject in need thereof, the method comprising administering to the subject a nucleic acid construct comprising: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain of TNF Recepto
1. A method of inducing apoptosis of an endothelial cell in a tumor of a subject in need thereof, the method comprising administering to the subject a nucleic acid construct comprising: (a) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain of TNF Receptor 1 (TNFR1) fused to an effector domain of Fas; and(b) a second polynucleotide region comprising a PPE-1-3X promoter, which directs expression of said chimeric polypeptide in the endothelial cell in the tumor;wherein said chimeric polypeptide, when expressed, induces apoptosis of the endothelial cell in the tumor of said subject and wherein the nucleic acid construct is administered systemically or locally. 2. The method of claim 1, further comprising administering TNFα to the subject. 3. The method of claim 1, wherein said administration is selected from the group consisting of: (i) systemic in-vivo administration;(ii) ex-vivo administration; and(iii) local in-vivo administration. 4. The method of claim 1, wherein the ligand binding domain of TNFR1 comprises an extracellular domain of TNFR1. 5. The method of claim 1, wherein the effector domain of Fas comprises a trans-membrane region and an intracellular region of Fas. 6. The method of claim 1, wherein the ligand binding domain of TNFR1 is an extracellular domain of TNFR1 and the effector domain of Fas is a trans-membrane region and an intracellular region of Fas. 7. The method of claim 1, wherein the administration is parenteral administration. 8. The method of claim 3, wherein the systemic administration is intramuscular, subcutaneous, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, or intra-tumoral administration. 9. The method of claim 1, wherein the subject is characterized by excessive or abnormal neovascularization in the tissue or cell, thereby inducing tumor growth. 10. The method of claim 9, wherein the subject is a mammal. 11. The method of claim 9, wherein the subject is a human. 12. The method of claim 1, wherein the chimeric polypeptide induces apoptosis of the endothelial cell, wherein the size of the tumor is decreased. 13. The method of claim 2, wherein the TNF-α is administered together with the nucleic acid construct. 14. The method of claim 1, wherein the tumor is a solid tumor. 15. The method of claim 1, wherein the tumor is a metastatic tumor. 16. The method of claim 1, wherein the nucleic acid construct comprises adenovirus. 17. The method of claim 1, wherein the nucleic acid construct comprises Ad-PPE-1-3X-Fas-chimera. 18. A method of inducing apoptosis of an endothelial cell in a tumor of a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a nucleic acid construct and a pharmaceutically acceptable carrier wherein the nucleic acid construct comprises:(a) a first polynucleotide region encoding a chimeric polypeptide comprising an extracellular domain of TNFR1 fused to a trans-membrane region and an intracellular region of Fas; and(b) a second polynucleotide region comprising a PPE-1-3X promoter, which directs expression of said chimeric polypeptide in the endothelial cell in the tumor;wherein said pharmaceutical composition induces apoptosis of the endothelial cell in the tumor of the subject and wherein the pharmaceutical composition is administered systemically or locally. 19. The method of claim 18, wherein the nucleic acid construct comprises Ad-PPE-1-3X-Fas-chimera. 20. The method of claim 18, wherein the pharmaceutical composition is administered intravenously or intra-tumorally. 21. A method of reducing a tumor size in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a nucleic acid construct and a pharmaceutically acceptable carrier, wherein the nucleic acid construct comprises:(a) a first polynucleotide region encoding a chimeric polypeptide comprising an extracellular domain of TNFR1 fused to a trans-membrane region and an intracellular region of Fas; and(b) a second polynucleotide region comprising a PPE-1-3X promoter, which directs expression of said chimeric polypeptide in the tumor;wherein said pharmaceutical composition reduces the tumor size in the subject and wherein the pharmaceutical composition is administered systemically or locally. 22. The method of claim 21, wherein the nucleic acid construct comprises Ad-PPE-1-3X-Fas-chimera. 23. The method of claim 21, wherein the pharmaceutical composition is administered intravenously or intra-tumorally. 24. The method of claim 1, wherein the endothelial cell is in a blood vessel of the tumor. 25. The method of claim 1, wherein the chimeric polypeptide induces necrosis of the tumor. 26. The method of claim 12, wherein the chimeric polypeptide further induces necrosis of the tumor.
Sogard David J. (Edina MN) Hendrickson Gary L. (New Hope MN) Wang Lixiao (St. Paul MN) Keith Pete T. (Fridley MN), Balloon catheter having nonlinear compliance curve and method of using.
Zaleske David J. ; Peretti Giuseppe,ITX ; Caruso Enzo ; Rossetti Francesco,ITX ; Randolph Mark, Bonding of cartilage pieces using isolated chondrocytes and a biological gel.
Wolinsky Harvey (New York NY) King Spencer L. (Atlanta GA) Barbere Michael D. (Dunstable MA), Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Auth David C. (Redmond WA) Intlekofer Michael J. (Bellevue WA) Slota Michael W. (Bothell WA) Hinchcliffe John S. (Seattle WA) Clement Thomas J. (Redmond WA), Clinically practical rotational angioplasty system.
Patterson, Paul H.; Lahav, Ronit, Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity.
Glines, Robert C.; Weller, Gary B., Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body.
Crocker Michael D. (Mission Viejo CA) Henson Michael R. (Pleasonton CA) Chum Muny (Santa Ana CA), Drug delivery and dilatation catheter having a reinforced perfusion lumen.
Valley Kirsten L. ; Snow David W. ; Corvi Timothy C. ; Donlon Brian S. ; Boyd Stephen W. ; Fan Sylvia W. ; Roth Alex T. ; Peters William S. ; Mueller ; Jr. Richard J. ; Gifford ; III Hanson S., Endovascular system for arresting the heart.
Michael E. Placke ; Anthony R. Imondi ; Michael J. Brooker ; John E. Frye ; Praful K. Shah ; Douglas R. Flanagan, Jr. ; Maureen D. Donovan, Formulation and method for treating neoplasms by inhalation.
Sedlacek Hans-Harald,DEX ; Bosslet Klaus,DEX ; Muller Rolf,DEX, Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound.
Flotte Thomas J. (Boston MA) Doukas Apostolos (Belmont MA) McAuliffe Daniel J. (Boxford MA) Anderson Therese M. (Brookline MA), High-pressure impulse transient drug delivery for the treatment of proliferative diseases.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
Chu Linag-Kuang,TWX ; Lin Chiao Po,TWX ; Shih Chien-Ming,TWX ; Lee Tsae Yueh,TWX ; Soong Tai-Sen,TWX, Method for preparing an environmentally compatable porous material comprising beneficial nematodes and the biotic preparations produced therefrom.
Machold Timothy R. (Moss Beach CA) Robinson Janine C. (Half Moon Bay CA) Michaels Mary B. (Sunnyvale CA) Sirhan Motasim M. (Sunnyvale CA), Method of delivery therapeutic or diagnostic liquid into tissue surrounding a body lumen.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Sterman, Wesley D.; Stevens, John H.; Gifford, III, Hanson S.; Siegel, Lawrence C.; Putnam, Joe B., Methods and apparatus for perfusion of isolated tissue structure.
Harats, Dror; George, Jacob; Halperin, Gideon, Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis.
Harats,Dror; George,Jacob; Halperin,Gideon, Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis.
Harats,Dror; George,Jacob; Halperin,Gideon; Yacov,Niva; Kovalevski Ishai,Eti, Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis.
Huber Brian ; Richards Cynthia A. ; Austin Elizabeth A., Molecular constructs comprising a carcinoembryonic antigen (CEA) transcriptional regulatory region.
Leopold Lance H. (Philadelphia PA) Shore Scott K. (Ardmore PA) Reddy Moole V. R. (Upper Darby PA) Reddy E. Premkumar (Villanova PA), Multi-unit ribozyme inhibition of oncogene gene expression.
Lilley Stephen John,GBX ; Taylor Hugh Francis,GBX ; Theobald David Reginald,GBX ; Carlson Craig J. ; Rosen David I. ; Johnson Thomas R., Nozzle assembly with lost motion connection for medical injector assembly.
Muneyoshi Takahiko,JPX ; Saito Atsushi,JPX, Optical information processing apparatus having small optical system using a plurality of beam expanding elements.
Harats, Dror; George, Jacob; Halperin, Gideon; Mendel, Itzhak, Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders.
Harats, Dror; George, Jacob; Halperin, Gideon; Yacov, Niva; Kovalevski-Ishai, Eti, Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders.
Harats, Dror; Greenberger, Shoshana; Breitbart, Eyal, Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy.
Harats, Dror; Greenberger, Shoshana; Breitbart, Eyal, Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy.
Harats, Dror; Greenberger, Shoshana; Breitbart, Eyal; Bangio, Livnat; Peled, Michael, Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis.
Harats, Dror; Greenberger, Shoshana; Breitbart, Eyal, Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy.
Harats, Dror; Greenberger, Shoshana; Breitbart, Eyal; Bangio, Livnat; Peled, Michael, Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.